Camilla Foged

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8527780/publications.pdf

Version: 2024-02-01

112 papers	6,173 citations	66343 42 h-index	76900 74 g-index
118 all docs	118 docs citations	118 times ranked	8121 citing authors

#	Article	IF	Citations
1	Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. International Journal of Pharmaceutics, 2005, 298, 315-322.	5.2	741
2	Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics, 2020, 12, 102.	4.5	320
3	High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 26-35.	4.3	191
4	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frontiers in Immunology, 2020, 11, 1817.	4.8	189
5	Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine, 2004, 22, 1903-1913.	3.8	181
6	Delivery of oligonucleotideâ€based therapeutics: challenges and opportunities. EMBO Molecular Medicine, 2021, 13, e13243.	6.9	181
7	Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opinion on Drug Delivery, 2008, 5, 105-117.	5.0	177
8	Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. Journal of Controlled Release, 2010, 142, 138-145.	9.9	176
9	The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology, 2007, 121, 216-226.	4.4	167
10	Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. Journal of Controlled Release, 2012, 157, 141-148.	9.9	162
11	Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics, 2016, 8, 7.	4.5	147
12	Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Therapeutic Delivery, 2011, 2, 1057-1077.	2.2	116
13	Stabilization of liposomes during drying. Expert Opinion on Drug Delivery, 2011, 8, 375-388.	5.0	114
14	License to kill: Formulation requirements for optimal priming of CD8+ CTL responses with particulate vaccine delivery systems. European Journal of Pharmaceutical Sciences, 2012, 45, 482-491.	4.0	103
15	Preparation and characterization of poly(dl-lactide-co-glycolide) nanoparticles for siRNA delivery. International Journal of Pharmaceutics, 2010, 390, 70-75.	5.2	98
16	Immunity by formulation design: Induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. Journal of Controlled Release, 2011, 150, 307-317.	9.9	85
17	Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opinion on Drug Delivery, 2009, 6, 657-672.	5.0	81
18	Calcipotriol delivery into the skin with PEGylated liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 532-539.	4.3	80

#	Article	IF	Citations
19	Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 2120-2129.	2.6	79
20	Anti-Inflammatory Effect of Anti-TNF-Î± SiRNA Cationic Phosphorus Dendrimer Nanocomplexes Administered Intranasally in a Murine Acute Lung Injury Model. Biomacromolecules, 2017, 18, 2379-2388.	5.4	78
21	Elucidating the molecular mechanism of PAMAMâ€“siRNA dendriplex self-assembly: Effect of dendrimer charge density. International Journal of Pharmaceutics, 2011, 416, 410-418.	5.2	77
22	Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. Journal of Controlled Release, 2015, 210, 48-57.	9.9	76
23	Molecular Characterization of the Interaction between siRNA and PAMAM G7 Dendrimers by SAXS, ITC, and Molecular Dynamics Simulations. Biomacromolecules, 2010, 11, 3571-3577.	5.4	75
24	Mechanistic profiling of the siRNA delivery dynamics of lipidâ€“polymer hybrid nanoparticles. Journal of Controlled Release, 2015, 201, 22-31.	9.9	66
25	The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8 + T-cell responses: The immunological consequences of the biodistribution profile. Journal of Controlled Release, 2016, 239, 107-117.	9.9	62
26	Critical Solvent Properties Affecting the Particle Formation Process and Characteristics of Celecoxib-Loaded PLGA Microparticles via Spray-Drying. Pharmaceutical Research, 2013, 30, 1065-1076.	3.5	59
27	Liposomes for phospholipase A2 triggered siRNA release: Preparation and in vitro test. International Journal of Pharmaceutics, 2007, 331, 160-166.	5.2	58
28	Nanoparticle-mediated delivery of the antimicrobial peptide plectasin against Staphylococcus aureus in infected epithelial cells. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 92, 65-73.	4.3	56
29	Cellular uptake and membrane-destabilising properties of Î±-peptide/Î²-peptoid chimeras: lessons for the design of new cell-penetrating peptides. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 2487-2495.	2.6	55
30	MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. Journal of Controlled Release, 2012, 161, 772-780.	9.9	55
31	CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. International Journal of Pharmaceutics, 2010, 390, 19-24.	5.2	54
32	Engineering of small interfering RNA-loaded lipidoid-poly(DL -lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 120, 22-33.	4.3	53
33	Incorporation of the TLR4 Agonist Monophosphoryl Lipid A Into the Bilayer of DDA/TDB Liposomes: Physico-Chemical Characterization and Induction of CD8+ T-Cell Responses In Vivo. Pharmaceutical Research, 2011, 28, 553-562.	3.5	51
34	siRNA Delivery with Lipid-based Systems: Promises and Pitfalls. Current Topics in Medicinal Chemistry, 2012, 12, 97-107.	2.1	51
35	Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. Journal of Controlled Release, 2017, 260, 78-91.	9.9	50
36	Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-Î± siRNA with PAMAM dendrimers in a murine model. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 114-120.	4.3	49

#	Article	IF	Citations
37	Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosanâ€“poly(ethylene imine) hybrid nanoparticles: A mechanistic insight. Journal of Controlled Release, 2015, 211, 1-9.	9.9	48
38	A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522. Journal of Controlled Release, 2018, 271, 88-97.	9.9	48
39	Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 89-98.	4.3	47
40	Trehalose diester glycolipids are superior to the monoesters in binding to Mincle, activation of macrophages inÂvitro and adjuvant activity inÂvivo. Innate Immunity, 2016, 22, 405-418.	2.4	47
41	Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 38-48.	4.3	46
42	Engineering of an Inhalable DDA/TDB Liposomal Adjuvant: A Quality-by-Design Approach Towards Optimization of the Spray Drying Process. Pharmaceutical Research, 2013, 30, 2772-2784.	3.5	44
43	Protein Antigen Adsorption to the DDA/TDB Liposomal Adjuvant: Effect on Protein Structure, Stability, and Liposome Physicochemical Characteristics. Pharmaceutical Research, 2013, 30, 140-155.	3.5	43
44	Antiplasmodial and Prehemolytic Activities of Î±â€Peptideâ€“Î²â€Peptoid Chimeras. ChemBioChem, 2007, 8, 1781-1784.	2.6	41
45	One-Step Production of Protein-Loaded PLGA Microparticles via Spray Drying Using 3-Fluid Nozzle. Pharmaceutical Research, 2014, 31, 1967-1977.	3.5	41
46	Targeting of liposome-associated calcipotriol to the skin: Effect of liposomal membrane fluidity and skin barrier integrity. International Journal of Pharmaceutics, 2011, 416, 478-485.	5.2	40
47	Improved insulin loading in poly(lactic-co-glycolic) acid (PLGA) nanoparticles upon self-assembly with lipids. International Journal of Pharmaceutics, 2015, 482, 84-91.	5.2	40
48	Inhalable siRNA-loaded nano-embedded microparticles engineered using microfluidics and spray drying. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 120, 9-21.	4.3	40
49	Identification of Factors of Importance for Spray Drying of Small Interfering RNA-Loaded Lipidoid-Polymer Hybrid Nanoparticles for Inhalation. Pharmaceutical Research, 2019, 36, 142.	3.5	39
50	Designing CAF-adjuvanted dry powder vaccines: Spray drying preserves the adjuvant activity of CAF01. Journal of Controlled Release, 2013, 167, 256-264.	9.9	38
51	Î±,Î±â€²-trehalose 6,6â€²-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 1365-1373.	2.6	36
52	Comparison of Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene Silencing, Toxicity and Off-Target Gene Expression. Pharmaceutical Research, 2012, 29, 669-682.	3.5	36
53	Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: Effect of charge, fluidity and antigen-to-lipid ratio. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 2001-2010.	2.6	35
54	Nebulised lipidâ€“polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells. ERJ Open Research, 2019, 5, 00161-2018.	2.6	35

#	Article	IF	Citations
55	Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder. Vaccine, 2018, 36, 3331-3339.	3.8	33
56	Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. Journal of Controlled Release, 2019, 310, 82-93.	9.9	33
57	Hyaluronic Acid-Based Nanogels Produced by Microfluidics-Facilitated Self-Assembly Improves the Safety Profile of the Cationic Host Defense Peptide Novicidin. Pharmaceutical Research, 2015, 32, 2727-35.	3.5	32
58	Engineering of budesonide-loaded lipid-polymer hybrid nanoparticles using a quality-by-design approach. International Journal of Pharmaceutics, 2018, 548, 740-746.	5.2	31
59	Interaction of Peptidomimetics with Bilayer Membranes: Biophysical Characterization and Cellular Uptake. Langmuir, 2012, 28, 5167-5175.	3.5	28
60	Polymeric Nanocarriers for siRNA Delivery: Challenges and Future Prospects. Journal of Biomedical Nanotechnology, 2008, 4, 258-275.	1.1	27
61	Immunogenicity Testing of Lipidoids InÂVitro and In Silico: Modulating Lipidoid-Mediated TLR4 Activation by Nanoparticle Design. Molecular Therapy - Nucleic Acids, 2018, 11, 159-169.	5.1	27
62	Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. International Journal of Pharmaceutics, 2022, 621, 121758.	5.2	26
63	Impact of PLGA molecular behavior in the feed solution on the drug release kinetics of spray dried microparticles. Polymer, 2013, 54, 5920-5927.	3.8	24
64	Modulating Protein Release Profiles by Incorporating Hyaluronic Acid into PLGA Microparticles Via a Spray Dryer Equipped with a 3-Fluid Nozzle. Pharmaceutical Research, 2014, 31, 2940-2951.	3.5	24
65	Nanoparticles for mucosal vaccine delivery. , 2020, , 603-646.		24
66	Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization. Frontiers in Immunology, 2018, 9, 2825.	4.8	23
67	Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge. Expert Opinion on Drug Delivery, 2014, 11, 1481-1495.	5.0	22
68	The Physical Stability of the Recombinant Tuberculosis Fusion Antigens H1 and H56. Journal of Pharmaceutical Sciences, 2013, 102, 3567-3578.	3.3	21
69	Lipid Shell-Enveloped Polymeric Nanoparticles with High Integrity of Lipid Shells Improve Mucus Penetration and Interaction with Cystic Fibrosis-Related Bacterial Biofilms. ACS Applied Materials & Interfaces, 2018, 10, 10678-10687.	8.0	21
70	Formulating Inhalable Dry Powders Using Two-Fluid and Three-Fluid Nozzle Spray Drying. Pharmaceutical Research, 2018, 35, 247.	3.5	21
71	Qualitative and quantitative analysis of the biophysical interaction of inhaled nanoparticles with pulmonary surfactant by using quartz crystal microbalance with dissipation monitoring. Journal of Colloid and Interface Science, 2019, 545, 162-171.	9.4	21
72	Phospholipase A₂Sensitive Liposomes for Delivery of Small Interfering RNA (siRNA). Journal of Liposome Research, 2007, 17, 191-196.	3.3	20

#	Article	IF	Citations
73	Membrane adsorption and binding, cellular uptake and cytotoxicity of cell-penetrating peptidomimetics with Îł-peptide/Î²-peptoid backbone: Effects of hydrogen bonding and Îł-chirality in the Î²-peptoid residues. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2660-2668.	2.6	20
74	The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 480-488.	4.3	20
75	Macrophage Phosphoproteome Analysis Reveals MINCLE-dependent and -independent Mycobacterial Cord Factor Signaling. Molecular and Cellular Proteomics, 2019, 18, 669-685.	3.8	20
76	NIR transmission spectroscopy for rapid determination of lipid and lyoprotector content in liposomal vaccine adjuvant system CAF01. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 914-920.	4.3	19
77	Influence of trehalose 6,6â€²-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 80-89.	4.3	19
78	Delivery of siRNA Complexed with Palmitoylated Îł-Peptide/Î²-Peptoid Cell-Penetrating Peptidomimetics: Membrane Interaction and Structural Characterization of a Lipid-Based Nanocarrier System. Molecular Pharmaceutics, 2016, 13, 1739-1749.	4.6	19
79	Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 140, 29-39.	4.3	19
80	Microfluidics-based self-assembly of peptide-loaded microgels: Effect of three dimensional (3D) printed micromixer design. Journal of Colloid and Interface Science, 2019, 538, 559-568.	9.4	19
81	Classification of Vaccines. Advances in Delivery Science and Technology, 2015, , 15-29.	0.4	18
82	Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities. Therapeutic Delivery, 2018, 9, 731-749.	2.2	18
83	Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C). Frontiers in Immunology, 2018, 9, 898.	4.8	18
84	Preparation, Characterization, and In Vitro Evaluation of Lipidoidâ€“Polymer Hybrid Nanoparticles for siRNA Delivery to the Cytosol. Methods in Molecular Biology, 2019, 1943, 141-152.	0.9	18
85	Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects. Pharmaceutics, 2021, 13, 177.	4.5	18
86	Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein. Journal of Controlled Release, 2018, 285, 12-22.	9.9	17
87	Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin Îł2Î²1 receptor. International Journal of Pharmaceutics, 2012, 428, 171-177.	5.2	16
88	The supramolecular structure is decisive for the immunostimulatory properties of synthetic analogues of a mycobacterial lipid in vitro. RSC Advances, 2013, 3, 20673-20683.	3.6	16
89	Mechanism of Action of Lung Damage Caused by a Nanofilm Spray Product. Toxicological Sciences, 2014, 140, 436-444.	3.1	16
90	Surface coating of siRNAâ€“peptidomimetic nano-self-assemblies with anionic lipid bilayers: enhanced gene silencing and reduced adverse effects in vitro. Nanoscale, 2015, 7, 19687-19698.	5.6	16

#	Article	IF	Citations
91	Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy. AAPS PharmSciTech, 2019, 20, 137.	3.3	16
92	Thermostable Subunit Vaccines for Pulmonary Delivery: How Close Are We?. Current Pharmaceutical Design, 2016, 22, 2561-2576.	1.9	16
93	Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone. Frontiers in Immunology, 2020, 11, 803.	4.8	15
94	A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4⁺ T-cell response. Nanomedicine, 2014, 9, 2625-2638.	3.3	13
95	Nano-Self-Assemblies Based on Synthetic Analogues of Mycobacterial Monomycoloyl Glycerol and DDA: Supramolecular Structure and Adjuvant Efficacy. Molecular Pharmaceutics, 2016, 13, 2771-2781.	4.6	12
96	Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA. Molecular Pharmaceutics, 2017, 14, 2294-2306.	4.6	11
97	Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery. Pharmaceutical Research, 2019, 36, 37.	3.5	11
98	Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF-Î± siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles. Frontiers in Bioengineering and Biotechnology, 2020, 8, 601155.	4.1	11
99	Evaluation of carrier-mediated siRNA delivery: Lessons for the design of a stem-loop qPCR-based approach for quantification of intracellular full-length siRNA. Journal of Controlled Release, 2013, 166, 220-226.	9.9	9
100	Adsorption of protein antigen to the cationic liposome adjuvant CAFÂ®01 is required for induction of Th1 and Th17 responses but not for antibody induction. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 293-305.	4.3	9
101	Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses. Pharmaceutical Research, 2017, 34, 1716-1727.	3.5	8
102	Insight into Nanoscale Network of Spray-Dried Polymeric Particles: Role of Polymer Molecular Conformation. ACS Applied Materials & Interfaces, 2018, 10, 36686-36692.	8.0	8
103	Temperature-Induced Self-Assembly of the Group B Streptococcus (GBS) Fusion Antigen GBS-NN. Molecular Pharmaceutics, 2018, 15, 2584-2593.	4.6	5
104	Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles. Molecular Pharmaceutics, 2019, 16, 4725-4737.	4.6	5
105	Conserved Molecular Superlattices in a Series of Homologous Synthetic Mycobacterial Cell-Wall Lipids Forming Interdigitated Bilayers. Langmuir, 2016, 32, 12693-12701.	3.5	4
106	Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Proteinâ€“Based Fusion Antigen CTH522 Into Protein Nanoparticles. Journal of Pharmaceutical Sciences, 2018, 107, 1690-1700.	3.3	3
107	Inhalable Composite Microparticles Containing siRNA-Loaded Lipid-Polymer Hybrid Nanoparticles: Saccharides and Leucine Preserve Aerosol Performance and Long-Term Physical Stability. Frontiers in Drug Delivery, 0, 2, .	1.6	3
108	Engineering of Solid Dosage Forms of siRNA-Loaded Lipidoidâ€“Polymer Hybrid Nanoparticles Using a Quality-by-Design Approach. Methods in Molecular Biology, 2021, 2282, 137-157.	0.9	2

#	Article	IF	Citations
109	Characterizing the Association Between Antigens and Adjuvants. Advances in Delivery Science and Technology, 2015, , 413-426.	0.4	2
110	Grand Challenges in Vaccine Delivery: Lessons Learned From the COVID-19 Vaccine Rollout. Frontiers in Drug Delivery, 0, 2, .	1.6	1
111	Lipid-based colloidal carriers for targeted siRNA delivery. Therapeutic Delivery, 2012, 3, 1245-1247.	2.2	0
112	Immune Reactions in the Delivery of RNA Interference-Based Therapeutics: Mechanisms and Opportunities. , 2019, , 441-472.		0